Oral administration of sucroferric oxyhydroxide during hemodialysis sessions against resistant hyperphosphatemia

Oral administration of sucroferric oxyhydroxide during hemodialysis sessions against resistant hyperphosphatemia - Sucroferric oxyhydroxide against hyperphosphatemia

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031337

Enrollment

Registered

2018-02-16

Start date

2017-04-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resistant hyperphosphatemia in maintenance hemodialysis patients

Interventions

Oral administration of chuwable tablets of sucroferric oxyhydroxide during hemodialysis sessions(1-6T in each session)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Resistant hyperphosphatemia in hemodialysis patients

Exclusion criteria

Exclusion criteria: patients with risk od aspiration

Design outcomes

Primary

Measure	Time frame
reduction of serum phosphate levels	—

Secondary

Measure	Time frame
Serum FGF-23 levels, adverse events	—

Countries

Japan

Contacts

Public ContactYoshitaka Maeda

JA Toride Medical Center Dialysis Center

yoshimaeda43@toride-medical.or.jp81-297-74-5551

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026